oligo

(redirected from Oligos)
Also found in: Dictionary, Encyclopedia.

ol·i·go

(ol'i-gō),
In molecular genetics, oligonucleotide.
Farlex Partner Medical Dictionary © Farlex 2012

ol·i·go

(ol'i-gō)
molecular genetics Oligonucleotide.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

oligo

In genetics, shorthand for oligonucleotide .
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
The increasing applications of oligos in nucleic acid array-based technologies, library preparation, NGS, genomics, nucleic acid-based detection, cell cultures, diagnostics, therapeutics, human identity testing, cloning, genetic engineering, and synthetic biology are also driving the growth of this market.
Agilent expects the demand for therapeutic oligo manufacturing to grow near 10% each year through 2025, to over $750 million by 2025.
Two pairs of oligos have been employed to detect dermatophytes in general and then specifically Trichophyton species using second pair of oligos (Spiliopoulou et al., 2015).
Three oligos for each translocation target were pooled in equimolar amounts (0.125 [micro]mo/L).
Oligos are essential for development of new clinical genetic tests, target enrichment in panel tests, primers for qPCR-based tests, and barcoding samples to enable multiplexing.
The region in the pink rectangle is amplified exclusively with one set of oligos.
AUMantagomir self-transfecting oligos serve as potent antagomirs by binding with miRNAs and prevent their hybridization with their target mRNAs.
The amended agreement provides the company with access to Locked Nucleic Acid oligos for use with all of its ultra-high sensitivity mutation enrichment technologies, including its Multiplexed ICE COLD-PCRTM (MX-ICP).
Each oligo manufactured undergoes strict QC by mass spectrornetry.
Illumina will provide Cold Spring Harbor Laboratory with 100,000 longmer oligos ...
This patent covers the use of CpG oligonucleotides (CpG oligos) to activate dendritic cells.
The Degussa Group, Dusseldorf, Germany, will acquire Genset Oligos, the oligonucleotide division of Genset S.A., Paris (France), for US $21.5 million, and merge it with Proligo, its subsidiary based in Boulder, Colorado.